Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients with advanced NSCLC and high (≥50%) PD-L1 expression
Read More
Read More
Read More
Learn more about the latest Signatera™ data in high-risk breast cancer: Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring
Watch Video
Read More
Read More
Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for
Watch Video
In this webinar, we explore how ctDNA can help bring clarity to common clinical scenarios including adjuvant treatment decision making, indeterminate findings and assessing treatment response.
Watch Video
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Watch Video
Watch Video
Clinical Applications for Signatera in Breast Cancer Surveillance
Watch Video
Loading More...